Sign In
Buy ARGX
$844.50
+13.71 (+1.65%)
At Close: Aug 04, 2026
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
06:00am, Monday, 09'th Jan 2023 GlobeNewswire Inc.
Reported $402 million in preliminary* full-year 2022 global net VYVGART sales
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
06:00am, Tuesday, 03'rd Jan 2023 GlobeNewswire Inc.
January 3, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
01:00am, Tuesday, 03'rd Jan 2023
January 3 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, to
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
06:00pm, Friday, 30'th Dec 2022
Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday
01:33pm, Thursday, 22'nd Dec 2022 Benzinga
Stifel raised argenx SE (NASDAQ: ARGX) price target from $471 to $478. Stifel analyst Alex Thompson maintained a Buy rating on the stock. argenx shares rose 1.1% to $387.07 in pre-market trading.
argenx Appoints Ana Cespedes to Board of Directors
09:01pm, Monday, 12'th Dec 2022 GlobeNewswire Inc.
December 12, 2022
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
04:30pm, Saturday, 10'th Dec 2022 GlobeNewswire Inc.
First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease
First immune thrombocytopenia (ITP) pl enary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease
Analyst Ratings for argenx
07:00pm, Wednesday, 07'th Dec 2022 Benzinga
argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
3
0
0
0
Last 30D
0
0
0
Expert Ratings for argenx
06:02pm, Wednesday, 07'th Dec 2022 Benzinga
Within the last quarter, argenx (NASDAQ:ARGX) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
3
0
0
0
Last 30D
0
0
argenx Enters Into Agreement To Acquire Priority Review Voucher
06:00am, Wednesday, 30'th Nov 2022 GlobeNewswire Inc.
Amsterdam, the Netherlands – November 30, 2022 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseas
Halozyme (HALO) Stock Rises 35% in the Year so Far: Here's Why
04:48pm, Friday, 25'th Nov 2022 Zacks Investment Research
Halozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong revenues on the back of robust demand for its new partnered drugs.
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
06:00am, Tuesday, 22'nd Nov 2022 GlobeNewswire Inc.
- Prescription Drug User Fee Act (PDUFA) target action date is March 20, 2023
argenx to Present at Upcoming Investor Conferences
06:00am, Monday, 07'th Nov 2022 GlobeNewswire Inc.
November 7, 2022Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today
argenx to Present at Upcoming Investor Conferences
01:00am, Monday, 07'th Nov 2022
November 7 , 2022 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, to
